RY 172.93 -0.271% SHOP 157.86 0.7274% TD 75.22 0.2532% ENB 59.74 0.5216% BN 81.36 0.9429% TRI 234.42 0.5404% CNQ 43.01 1.2% CP 104.55 0.7225% CNR 146.44 0.7568% BMO 139.17 0.2377% BNS 77.04 -0.0649% CSU 4487.8101 0.7917% CM 91.94 -0.6054% MFC 44.04 1.1716% ATD 80.33 -0.5694% NGT 54.77 -0.635% TRP 66.14 0.532% SU 50.335 1.4819% WCN 245.2 -2.104% L 191.84 0.64%

ZYUS Life Sciences Corporation

Healthcare CA ZYUS

0.8CAD
-0.03(3.61%)

Last update at 2024-12-23T17:47:00Z

Day Range

0.720.88
LowHigh

52 Week Range

0.711.19
LowHigh

Fundamentals

  • Previous Close 0.83
  • Market Cap58.00M
  • Volume13500
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-16.56200M
  • Revenue TTM0.43M
  • Revenue Per Share TTM0.006
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.55

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31
Income before tax -48.43900M -24.71500M -23.57200M
Minority interest - - -
Net income -42.59100M -24.65700M -23.45500M
Selling general administrative 12.60M 9.45M 13.11M
Selling and marketing expenses - - -
Gross profit 0.17M -0.23200M 0.14M
Reconciled depreciation 3.11M 4.04M 3.78M
Ebit - - -
Ebitda - - -
Depreciation and amortization - - -
Non operating income net other - - -
Operating income -17.19200M -16.29500M -22.76900M
Other operating expenses - - -
Interest expense 3.27M 5.24M 2.74M
Tax provision -5.84800M -0.05800M -0.11700M
Interest income - - -
Net interest income -3.84500M -5.46400M -2.74200M
Extraordinary items - - -
Non recurring - - -
Other items - - -
Income tax expense - - -
Total revenue 0.35M 0.30M 0.21M
Total operating expenses 17.54M 16.59M 22.98M
Cost of revenue 0.18M 0.53M 0.06M
Total other income expense net -27.40200M -2.95600M 1.94M
Discontinued operations - - -
Net income from continuing ops -42.59100M -24.65700M -23.45500M
Net income applicable to common shares - - -
Preferred stock and other adjustments - - -
Breakdown 2023-12-31 2022-12-31
Type yearly yearly
Date 2023-12-31 2022-12-31
Total assets 41.63M 64.71M
Intangible assets 12.32M 35.39M
Earning assets - -
Other current assets 0.87M 1.61M
Total liab 18.51M 59.97M
Total stockholder equity 23.11M 4.74M
Deferred long term liab - -
Other current liab - -
Common stock - -
Capital stock 154.09M 92.67M
Retained earnings -140.18700M -97.59600M
Other liab - -
Good will 5.87M 5.87M
Other assets - -
Cash 3.98M 0.21M
Cash and equivalents - -
Total current liabilities 13.24M 14.27M
Current deferred revenue - -
Net debt 2.81M 31.49M
Short term debt - -
Short long term debt 6.15M 0.90M
Short long term debt total - -
Other stockholder equity - -
Property plant equipment - -
Total current assets 9.39M 6.27M
Long term investments - -
Net tangible assets - -
Short term investments 1.87M 0.00000M
Net receivables 0.16M 0.20M
Long term debt 0.64M 30.80M
Inventory 2.04M 4.20M
Accounts payable 3.44M 8.51M
Total permanent equity - -
Noncontrolling interest in consolidated entity - -
Temporary equity redeemable noncontrolling interests - -
Accumulated other comprehensive income - -
Additional paid in capital - -
Common stock total equity - -
Preferred stock total equity - -
Retained earnings total equity - -
Treasury stock - -
Accumulated amortization - -
Non currrent assets other 0.15M 0.16M
Deferred long term asset charges - -
Non current assets total 32.24M 58.45M
Capital lease obligations 3.02M 3.21M
Long term debt total - -
Breakdown 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31
Investments 4.64M -0.59200M -4.98900M
Change to liabilities - - -
Total cashflows from investing activities - - -
Net borrowings - - -
Total cash from financing activities 17.14M 9.63M 14.61M
Change to operating activities - - -
Net income -42.59100M -24.65700M -23.45500M
Change in cash 3.77M -0.53800M -7.24300M
Begin period cash flow 0.21M 0.75M 7.99M
End period cash flow 3.98M 0.21M 0.75M
Total cash from operating activities -18.01200M -9.57400M -16.86000M
Issuance of capital stock 0.00000M 0.17M 0.00800M
Depreciation 3.11M 4.04M 3.78M
Other cashflows from investing activities - - -
Dividends paid - - -
Change to inventory -0.02100M 0.45M -0.17000M
Change to account receivables -0.34700M 0.10M 0.33M
Sale purchase of stock - - -
Other cashflows from financing activities - - -
Change to netincome - - -
Capital expenditures 0.28M 0.56M 4.99M
Change receivables - - -
Cash flows other operating - - -
Exchange rate changes - - -
Cash and cash equivalents changes - - -
Change in working capital -4.81400M 2.62M 2.17M
Stock based compensation 0.27M 0.11M 0.62M
Other non cash items 5.99M 5.32M 2.46M
Free cash flow -18.29300M -10.13400M -21.84900M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ZYUS
ZYUS Life Sciences Corporation
-0.03 3.61% 0.80 - - 135.51 3.73 157.30 -4.258
RX
Biosyent Inc.
0.02 0.17% 11.76 18.58 15.70 3.82 3.65 3.34 11.28
LOVE
Cannara Biotech Inc
-0.03 4.00% 0.72 11.00 - 0.77 0.73 1.34 6.59
LSL
LSL Pharma Group Inc.
0.04 11.94% 0.38 - - 3.91 2.88 4.85 636.87
SBBC
Simply Better Brands Corp
0.01 0.99% 1.02 - 14.14 0.67 1.18 0.51 -5.4938

Reports Covered

Stock Research & News

Profile

ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates in Canada and internationally. The company offers cannabinoid oils, softgel capsules, and topical creams. ZYUS Life Sciences Corporation was founded in 2018 and is based in Saskatoon, Canada.

ZYUS Life Sciences Corporation

Unit 204, Saskatoon, SK, Canada, S7N 4L8

Key Executives

Name Title Year Born
Mr. Brent H. Zettl President, CEO, Secretary & Director 1962
Mr. John M. Hyshka Chief Financial Officer NA
Mr. Keith Carpenter CFA Chief Strategy & Investment Officer NA
Ms. Michelle Gursky Vice President of Legal Affairs NA
Dr. Lionel Marks de Chabris Chief Medical Officer NA
Mr. Tim Miller Director of Investor Relations & Capital Markets NA
Mr. Scott William Livingstone Vice President of Clinical Research NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.